# Junta clínica — PT-pseudo_c03b1168ff4d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c03b1168ff4d",
  "pid": "PT-pseudo_c03b1168ff4d",
  "task": 1,
  "psa": 7.8,
  "age": 74,
  "months": 2,
  "pirads": "4",
  "psad": 0.165,
  "psav": 1.2,
  "psap": 6.3,
  "vol": 47.17,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.75055045,
  "medhx": "Hypertension, Hypercholesterolaemia, Chronic kidney disease",
  "meds": "valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "87 kg",
    "height": "184 cm",
    "bmi": "25.7",
    "bp": "143/82 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (34 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "05 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment."
    },
    {
      "s": "History",
      "t": "A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema."
    }
  ],
  "occupation": "ICT consultant",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Audiology — hearing test"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 26/35 (severe LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c03b1168ff4d
Task: 1

Encounter: Urology - outpatient on 05 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.165 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 47.17 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.75055045 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.

Vitals: weight 87 kg, height 184 cm, BMI 25.7, BP 143/82 mmHg, HR 81 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2006).

Chief complaint: Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment.

History: A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable.

Physical examination: Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema.

Patient info: ICT consultant; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 26/35 (severe LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Audiology — hearing test.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.15 (95% CI 0.34-0.94); among patients it cannot tell apart the outcome was 0.94 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy after a negative biopsy should be considered dependent on risk factors such as PSA density and PI-RADS score. It states, "follow-up or direct repeat biopsy should be considered dependant of risk factors (e.g. PSA density, PI-RADS score)."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently grounded in the guideline because it fails to account for the specific thresholds the guideline sets. The guideline requires consideration of variables like PSA density and PI-RADS score to determine the need for a repeat biopsy, which the classifier's bid did not incorporate.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 4, which is a high-risk category, suggesting that the guideline requires consideration of this score when deciding on further steps.
PSA density - The PSA density is 0.165 ng/mL², which is a variable the guideline makes decisive, as it is listed as a risk factor for repeat biopsy consideration.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor the guideline uses to frame the decision pathway for subsequent management.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor the guideline uses to frame the decision pathway for subsequent management.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS score and PSA density, as highlighted by the EAU guideline, warrant a repeat biopsy given the prior positive result.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, specifically regarding lesion characteristics and comparison to prior studies.
  previous_notes (get_previous_notes) -> Establish the management context following the prior positive biopsy.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose specify the characteristics of the PI-RADS 4 lesion that influence the decision?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on. Dropped 1 question(s) that asked for a value already printed on the panel: "How does the PSA density of 0.165 ng/mL² interact with the PI-RADS score of 4 in the context of the EAU guideline?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose specifies the characteristics of the PI-RADS 4 lesion by describing an asymmetric hypointense area in the left peripheral zone, sized roughly 14 x 11 x 16 mm, with restricted diffusion and focal enhancement.
previous_notes
The management context following the prior positive biopsy involved initial consultation in January 2023, a positive biopsy result, and ongoing monitoring of renal function and lipid profiles.
psa_trend
The serial PSA has shown a rising trend from 1.5 ng/mL in June 2022 to 3.4 ng/mL in September 2023, and further to 7.8 ng/mL in January 2025.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not ask for a specific question justifying it, and the headline values were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a PI-RADS 4 lesion, which aligns with the EAU guideline's requirement to consider this score.
The PSA trend shows a clear rising trajectory, which is a factor in the decision pathway.
AGAINST sampling this patient now
The prior biopsy status is 'Positive', which is a critical factor the guideline uses to frame the decision pathway.

WHERE THIS LEANS
The data suggests that the high-risk PI-RADS score and the rising PSA trend strongly support considering further investigation, despite the prior positive biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, previous_notes, and psa_trend—have answered the moderator's question Q1 by specifying the characteristics of the PI-RADS 4 lesion (asymmetric hypointense area, restricted diffusion, focal enhancement).

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the mpMRI prose indicates a PI-RADS 4 lesion, which the EAU guideline requires consideration of.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose specify the characteristics of the PI-RADS 4 lesion that influence the decision? Answered by the registrar with the radiology_report, which describes the lesion characteristics.
Q2. What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period? Answered by the registrar with the psa_trend, showing a rising trend from 1.5 ng/mL in June 2022 to 7.8 ng/mL in January 2025.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS score (4) because it is a high-risk category requiring consideration per the EAU guideline, and the PSA trend because the serial PSA shows a clear rising trajectory, which is a factor in the decision pathway. The prior positive biopsy status is a variable the room has been leaning on, but the guideline frames the decision pathway around the PI-RADS and PSA density.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the high-risk PI-RADS score and the rising PSA trend strongly support further investigation despite the prior positive biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Deferral is appropriate because the patient has a prior positive biopsy, meaning the diagnosis is already established, and the panel does not contain information that would change the management pathway. Although the PI-RADS score was 4 and the PSA trend was rising, the established prior diagnosis means further tissue sampling is not indicated at this time. The room converged on deferral because the prior positive result is a critical factor that settles the decision.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, previous_notes, psa_trend
